The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Kaken's Japan sales performance.
BMS led the charge when Opdivo became the first in its class to gain approval (in metastatic melanoma in December 2014 in Japan), but Merck &Co’s Keytruda has emerged as
The drug is also under regulatory review for this indication in the US and Japan, and the new use could help AZ compete in the market with SGLT2 rivals Invokana (canagliflozin)
Ashfield operates across a further three regions – US, Japan and Europe, but hopes the new alliance will provide further expertise in data-driven market and events management.
the next few years in the 3% to 6% range, mainly due to sluggish growth in Europe, and static or shrinking sales in Japan. ... On the other hand, in Japan for example it says that growth in new products will be strong and resistant to price cuts, despite
The context here is worth keeping in mind. According to World Bank figures, Korea (4.2%), Japan (3.3%), the United States (2.8%), Germany (2.8%), Switzerland (2.4%), France
We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...